tbuckley/cabot-search huggingface dataset:
ATPS-36ETHNOMEDICAL SURVEY AND SCIENTIFIC VALIDATION OF ANTICANCER ACTIVITIES OF SOME NIGERIAN HERBAL PLANTS
Authors: Isa Hussaini, Ibrahim Iliya, Bala Audu
Journal: Neuro-Oncology (2015)

Cancer is the second leading cause of death in many countries and there is no cure for different forms of the disease. In Africa, traditional medicine practitioners (TMP) claim to have effective treatments for what they diagnose as “cancers”. This study used tissue culture and cancer cell viability techniques to validate the rationale for the folkloric use of herbal medications by TMP. We worked with a well-established TMP (Engineer Ali Musa Audu) to collect medicinal plants used in the treatment of cancers (daji) in the North-east geopolitical zone of Nigeria. We identified 42 plants that are used in the folkloric treatment of cancers and the botanical names were authenticated by a Taxonomist. The plant parts used in folkloric medicine were defatted with petroleum ether and further extracted with ethanol. The dried ethanol extracts were screened for anticancer cell viability activities against well-characterized brain tumour (A171, U87 and U1242) and breast cancer (231) cell lines. We screened 42 extracts and established robust anticancer cell viability activities of 8 herbal plants with concentration that inhibited 50% cell viability of less than 62.0 mg/ml. Three of the plant extracts were also tested on normal human astrocytes and showed toxicity only at higher concentration of 250.0 mg/ml. This is the first report of anticancer activities of medicinal plants from the North-east geopolitical zone of Nigeria.
Targeting CD22 in Childhood B-Precursor Acute Lymphoblastic Leukemia (Pre-B ALL): Pre-Clinical Studies and Phase I Trial of the Anti-CD22 Immunotoxin CAT-3888 (BL22).
Authors: Alan S. Wayne, Harry W. Findley, Glen Lew, Yachna Ahuja, Lubing Gu, Maryalice Stetler-Stevenson, Robert J. Kreitman, Ira Pastan
Journal: Blood (2007)
Bortezomib in Combination with Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin (V-DCEP) for the Treatment of Multiple Myeloma
Authors: Kelly Valla, Jonathan L. Kaufman, Charise Gleason, Lawrence H. Boise, Leonard T Heffner, Sanjay Manubolu, Aditya Singh Bisht, Melanie Watson, Ajay K. Nooka, Sagar Lonial
Journal: Blood (2014)
FRI0299 Pulmonary Arterial Hypertension in Idiopathic Inflammatory Myopathies: Data from The French Pulmonary Hypertension Registry and Review of The Literature
Authors: S. Sanges, C. Yelnik, O. Sitbon, O. Benveniste, K. Mariampillai, M. Phillips-Houlbracq, C. Pison, C. Deligny, J. Inamo, V. Cottin, L. Mouthon, D. Launay, M. Lambert, P.-Y. Hatron, L. Rottat, M. Humbert, E. Hachulla
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Occurrence of pulmonary arterial hypertension (PAH) in idiopathic inflammatory myopathies (IIM) without extensive interstitial lung disease (ILD) has been rarely described. <h3>Objectives</h3> This study aimed to report all cases with association of PAH and IIM in the French Pulmonary Hypertension (PH) Registry, to identify IIM features associated with PAH, and to describe treatment modalities of these patients. <h3>Methods</h3> All cases of IIM-PAH were retrieved from the French PH Registry, which gathers PAH patients prospectively enrolled by 21 referral centers across France. Patients were excluded if they had an extensive ILD or overlap syndrome. Characteristics of IIM-PAH patients were compared to a control group of IIM patients without PH. <h3>Results</h3> Among the 5223 PAH patients in the Registry, 34 had a diagnosis of IIM. Among them, 3 IIM-PAH patients had no sign of extensive ILD or overlap syndrome, and were included in this study. In these patients, dermatomyositis (DM) was the only identified IIM. Two of them had a myopathic DM, confirmed by electromyography and biopsy. The last patient had an amyopathic DM, associated with anti-Ku antibodies. Pre-capillary PH was hemodynamically proven in all patients. PAH always developed after IIM onset, was severe in all cases, and led to a marked functional impairment. By pooling our cases with 6 previously reported patients, and comparing them to a control cohort of 35 IIM patients without PH, we identify several IIM characteristics possibly associated with PAH occurrence, including DM subtype (78% vs. 46%, <i>p</i>=0.02), skin involvement (<i>p</i>=0.04), anti-SSA antibodies (<i>p</i>=0.05) and peripheral microangiopathy (<i>p</i>=0.06). Overall, IIM-PAH patients were managed by corticosteroids and/or immunosuppressants, either alone or combined with PAH therapy. Patients that did not receive PAH therapy did not seem to respond to IIM treatment alone. <h3>Conclusions</h3> Our study reports for the first time the rare but possible association of PAH and IIM in a large prospective PH Registry. In that setting, PAH seems associated with DM, skin involvement, peripheral microangiopathy and anti-SSA positivity. The best therapeutic strategy for IIM-PAH remains to be defined. <h3>Disclosure of Interest</h3> None declared
SP0032 Collaboration between Research and Patient Organisations: Improving Patient Care through The Danish Rheumatologic Biobank
Authors: B. Glintborg
Journal: Annals of the Rheumatic Diseases (2016)

Within the field of rheumatology, the number of available medical treatments is steadily increasing. During the last decades the biological disease modifying drugs (bDMARDs) have significantly improved outcomes for patients otherwise refractory to treatment. However, adverse effects, insufficient drug response and subsequent switching from one drug to another remain a significant problem for numerous patients in daily clinical practice. Within the field of oncology, personalized treatment strategies have come a long way. But for patients with inflammatory rheumatic diseases, the ability to choose the right drug for the right patient is still limited or non-existing. International treatment guidelines all follow a “one-size-fits-all” or “trial-and-error” strategy. The nationwide Danish Rheumatologic Biobank was established in year 2015 and is funded by the patient organization The Danish Rheumatism Association and the public hospital owners (Danish Regions). The aim of the Danish Rheumatologic Biobank is to promote the identification of new biomarkers for personalised treatment of patients with inflammatory rheumatic diseases. Biological samples (blood, synovial fluid etc.) are collected after written informed patient consent for specific research projects. Corresponding high-quality clinical data are registered prospectively in the nationwide quality and research registry, DANBIO. The treating physician registers patient demographics, previous and current treatment (DMARDs) including reasons for withdrawal, and physician-reported outcomes (clinical characteristics, treatment response, imaging) whereas the patient provides patient-reported outcomes (functional status, pain/fatigue/global scores). Danish Rheumatologic Biobank exemplifies a unique collaboration between patients and researchers, patient organisations and hospital owners aiming to pave the road for personalized treatment of patients with inflammatory rheumatic diseases. We expect the Danish Rheumatologic Biobank to facilitate high quality research and improved patient care within the field of rheumatology. During this lecture the rationale, infrastructure and status for DRB will be discussed. Acknowledgements: The Danish Rheumatism Association and the Danish Regions for funding. The DANBIO registry for hosting clinical data. The Danish Departments of Rheumatology and Biochemistry for participating in DRB sample collection. Thanks to professor Merete Lund Hetland, the main initiator of DRB and the working group behind DRB: Estrid Høgdall, Tina Kringelbach and Julia Sidenius Johansen. <h3>Disclosure of Interest</h3> None declared
Randomized Comparison of Cladribine Single (C) or in Combination with Cyclophosphamide (CC), and COP in Previously Untreated Low Grade B-Cell Non-Hodgkin Lymphoma Patients.
Authors: E. Kalinka, J. Wajs, K.S. Sulek, M. Blasinska-Morawiec, P. Centkowski, B. Ceglarek, T. Robak, J. Holowiecki, G. Mazur, I. Federowicz, W. Jedrzejczak, M. Watek, K. Warzocha
Journal: Blood (2006)
X-Linked Sideroblastic Anemia Is a Rare Cause of Microcytosis and Iron Overload in Adults: About 3 Cases with 2 New ALAS2 Gene Mutations Improved after Iron Chelation by Phlebotomy.
Authors: Mohamed Touati, Franck Trimoreau, Marie-Pierre Gourin-Chaury, Caroline Kannengiesser, Pascal Turlure, Veronique Loustaud-Ratti, Brigitte Gilbert-Dussardier, Bernard Grandchamp, Dominique Bordessoule
Journal: Blood (2007)
ASN002: A Potent Dual SYK/JAK Inhibitor Currently in a Phase I/II Study Shows Strong Antitumor Activity in Preclinical Studies
Authors: Niranjan S. Rao, Sanjeeva Reddy, Gupta Sandeep, Nitin K Damle, Venkatesan M Aranapakam, Scott Thompson, Roger Smith, Terry Plasse, Penelope Bristow, Anthony Tolcher, Kyriakos P Papadopoulos, Amita Patnaik, Drew W Rasco
Journal: Blood (2015)
Impact of Gender: Female Related Donor Versus Male Matched Unrelated Donor on Peripheral Blood Allogeneic Stem Cell Transplant for Male Recipients
Authors: Shatha Farhan, Edward Peres, Danielle Pelland, Susan Wautelet, Klodiana Neme, Nancy Mikulandric, Kenneth Ruemenapp, Mary Ann Trapp, Sarah Szymanski, Nalini Janakiraman
Journal: Blood (2014)
SAT0258 Assessing Myocardial Deformation of Kawasaki Patients with Speckle-Tracking Echocardiography on Long Term Follow Up
Authors: S. Sahin, R. Dedeoglu, F. Oztunc, K. Barut, A. Adrovic, S.U. Atik, D. Cengiz, O. Kasapcopur
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Myocardial dysfunction due to coronary arterial lesions is an important complication after Kawasaki disease in childhood (1,2). Speckle-tracking echocardiography (STE) is a recently developed technique for evaluation of myocardial deformation (3). <h3>Objectives</h3> Our objective was to examine myocardial deformation at long term follow-up of Kawasaki patients. <h3>Methods</h3> We assessed regional myocardial function in 32 asymptomatic Kawasaki patients and 30 age matched healthy child as control group. STE examination were recorded and the acquired raw data were saved for offline analysis The inferoseptal, anterolateral, inferior, anterior, and inferolateral (posterior) walls were investigated for longitudinal systolic peak values for strain (LV-SR) imaging. <h3>Results</h3> Mean age was 21±12 months, mean follow up time 61 months, Left ventricular ejection fraction was 57,373±8,338 in patients and 61,100±3,804 in control group. LV-SR of Kawasaki patients at basal-inferoseptal (20,000±6,046 vs 25,200±5,074), basal-anterolateral (19,595±5,713 vs 22,733±3,494), apical-septal (23,378±5,609 vs 26,267±4,334), apical-inferior (24,054±3,696 vs 25,200±2,396) segments had lower values than control group. <h3>Conclusions</h3> We demonstrated subclinical systolic impairment of function especially at left ascending artery territories with STE. STE has the potential to detect these subtle abnormalities, and help management during long term follow up. <h3>References</h3> Printz BF, et al. Noncoronary cardiac abnormalities are associated with coronary artery dilation and with laboratory inflammatory markers in acute Kawasaki disease. Journal of the American College of Cardiology 2011;57(1): 86–92. Xu QQ, et al. Evaluation of left ventricular systolic strain in children with Kawasaki disease. Pediatric cardiology 2014;35(7): 1191–1197. Marwick TH, et al. Myocardial strain measurement with 2 dimensional speckle-tracking echocardiography: definition of normal range. JACC: Cardiovascular Imaging 2009;2(1): 80–84. <h3>Disclosure of Interest</h3> None declared
SP0064 Pathogenic Memory Plasma Cells in Rheumatic Diseases - A Critical Target of Therapy
Authors: A. Radbruch
Journal: Annals of the Rheumatic Diseases (2016)

Plasma cells can contribute to rheumatic inflammation through the secretion of pathogenic (auto)antibodies. While autoreactive plasma blasts are short-lived products of the chronic inflammation, autoreactive memory plasma cells can be generated already early on, in the preclinical phase, and continuously thereafter. They are refractory to conventional immunosuppressive therapy, such as glucocorticoids, anti-TNF or anti-CD20 antibodies, aiming at the termination of ongoing immune reactions. Memory plasma cells secreting pathogenic antibodies thus can provide the memory for chronic inflammation. In diagnostic terms, titers of (auto)antibodies maintained in spite of immunosuppressive therapy, in a given patient, indicate the presence of memory plasma cells secreting them: A therapeutic challenge. Memory plasma cells reside in special survival niches within the bone marrow, but also in the inflamed tissue itself, resting in terms of proliferation and mobility. They do not express CD20. They are not long-lived intrinsically, but kept alive by survival factors, such as VCAM1 and APRIL, provided by stroma cells and accessory cells of their survival niche. Understanding the lifestyle of memory plasma cells has provided strategic options to target them, but so far almost all therapeutic options do not discriminate between pathogenic and protective plasma cells, and thus imply loss of humoral memory and increased risk of infections. The therapeutic challenge is to ablate pathogenic plasma cells selectively and maintain protective humoral memory as much as possible, and to prevent regeneration of memory plasma cells from their precursors. <h3>Disclosure of Interest</h3> None declared
FRI0573 Integration of Time-Averaged DAS28 Fits Better Joint Destruction In Rheumatoid Arthritis Than One-Time DAS28 and Identifies A Significant Joint-Destructive Association of HLA-DRB1*04:05 Which is Independent of ACPA and DAS28
Authors: H. Tsuji, C. Terao, K. Yano, K. Ikari, M. Hashimoto, M. Furu, H. Ito, T. Fujii, W. Yamamoto, N. Yamakawa, K. Ohmura, A. Taniguchi, S. Momohara, H. Yamanaka, F. Matsuda, T. Mimori
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Disease Activity Score 28 (DAS28) is one of correlates of joint destruction in rheumatoid arthritis (RA) as well as genetic components, RA-related autoantibodies, and disease duration. Joint destruction is considered to reflect the cumulative history of the disease activities, but one-time DAS28 is used in many studies. Relationship among the correlates is still unclear, while we previously showed that HLA-DRB1*04:05 is associated with joint destruction independently of anti-citrullinated protein antibody (ACPA). <h3>Objectives</h3> We hypothesized the superiority of time-averaged DAS28 to one-time DAS28 to fit the model to assess joint destruction. We also hypothesized that DRB1*04:05 might be associated with joint destruction independently of ACPA and DAS28. <h3>Methods</h3> We recruited RA patients in the KURAMA (n=204) and IORRA cohort (n=557) whose data of modified Sharp/van der Heijde score (SHS), consecutive DAS28, and other correlates of SHS were available. We calculated time-averaged DAS28 and modeled SHS using time-averaged DAS28 and the other covariates. We randomly picked up DAS28 in each patient and constructed 1000 sets of DAS28 to model SHS. We empirically evaluated fitting of the model using time-averaged DAS28 among the 1000 models using one-time DAS28. Next, we analyzed an association between DRB1*04:05 and SHS of ACPA (+) patients in KURAMA (n=100) and IORRA (n=472). <h3>Results</h3> In conditioned for the autoantibodies and disease duration, the time-averaged DAS28 showed significant improvement of model fitting in comparison with one-time DAS28 (R<sup>2</sup> in KURAMA: p=0.037, R<sup>2</sup> in IORRA: p=0.001). Generalized linear regression model in ACPA (+) patients showed a significant association between DRB1*04:05 and SHS (overall p=0.0002) in conditioned for time-averaged DAS28 and the other covariates. We observed this significant association even in patients whose time-averaged DAS28 was in low disease activity or remission. <h3>Conclusions</h3> Time-averaged DAS28 fits SHS better than one-time DAS28 and usage of time-averaged DAS28 as a covariate would increase the power of studies to identify novel correlates of SHS. DRB1*04:05 demonstrates an association with joint destruction which is independent of ACPA and even DAS28 by using time-averaged DAS28, suggesting necessity of strong treatment for RA patients carrying DRB1*04:05 even when they are in low disease activity or remission. <h3>References</h3> Navarro-Compán V, et al. Rheumatology. 2015 54(6):994–1007. Terao C, et al. Arthritis Rheumatol. 2015 67(7):1744–50. <h3>Disclosure of Interest</h3> None declared
Administration of a Novel GDF Trap Prevents Anemia Induced by Renal Insufficiency and Augments Recovery From Blood Loss.
Authors: Samuel M. Cadena, Dianne Mitchell, Jeff Ucran, Katia Liharska, Dianne Sako, Travis Monnell, Ravindra Kumar, Kathryn W. Underwood, R. Scott Pearsall
Journal: Blood (2009)
Vitiligo and depression: a systematic review and meta‐analysis of observational studies
Authors: Y.C. Lai, Y.W. Yew, C. Kennedy, R.A. Schwartz
Journal: British Journal of Dermatology (2016)

Vitiligo is a common depigmenting disorder with profound psychosocial impacts. Previous observational studies have suggested a link between vitiligo and psychiatric morbidity, such as depression. However, variability in study design makes it difficult to quantify accurately the relationship between vitiligo and depression. We aimed to investigate the underlying prevalence and risk of depression among patients with vitiligo. A comprehensive search of MEDLINE, Embase and the Cochrane Library was conducted. Cross-sectional, case-control or cohort studies that assessed the prevalence of depression among patients with vitiligo or the relationship between vitiligo and depression were included. DerSimonian and Laird random-effects models were utilized to calculate the pooled prevalence and relative risks. Publication bias was evaluated by funnel plots and Egger's tests. Twenty-five studies with 2708 cases of vitiligo were included. Based on diagnostic codes, the pooled prevalence of depression among patients with vitiligo was 0·253 [95% confidence interval (CI) 0·16-0·34; P < 0·001)]. Using self-reported questionnaires, the pooled prevalence of depressive symptoms was 0·336 (95% CI 0·25-0·42; P < 0·001). The pooled odds ratio of depression among patients with vitiligo was 5·05 vs. controls (95% CI 2·21-11·51; P < 0·001). Moderate-to-high heterogeneity was observed between the studies. Patients with vitiligo were significantly more likely to suffer from depression. Clinical depression or depressive symptoms can be prevalent, with the actual prevalence differing depending on screening instruments or, possibly, geographical regions. Clinicians should actively evaluate patients with vitiligo for signs/symptoms of depression and provide appropriate referrals to manage their psychiatric symptoms accordingly.
Vaccine treatment using cultured autologous tumor cells in patients with recurrent, metastatic, or high-risk renal cell carcinoma
Authors: Robert O. Dillman, Senthamil Selvan, Linda D. Beutel, Cristina De Leon, Carol Depriest, Cheryl Peterson, Audrey A. O’Connor, Shankar K. Nayak
Journal: Cancer Research (2004)

1247   Between 1991-2001 we attempted to produce tumor cell lines from patients with advanced kidney cancer [Dillman et al,  Cancer Biother Radiopharm  16:47-54, 2001]. Here we report the results from treating 26 kidney cancer patients with their patient-specific whole tumor cell vaccines derived from the short-term autologous tumor cell lines. 100 million cells from successful short-term cell lines were irradiated, frozen in aliquots of 10 7  cells, then thawed and administered s.c. once a week for 3 weeks, then once a month for 5 months. Various adjuvants were co-administered with each vaccine including GM-CSF, interferon-γ, interferon-α, and BCG. Patients included 20 men and 6 women, 43-82 years of age (median 53). At the time of treatment, 17 patients had distant metastatic disease, 3 had regional extension or spread of disease, and 6 had a large primary lesion. Vaccine therapy was well tolerated. Delayed type hypersensitivity (DTH) tests of 10 6  irradiated tumor cells, injected i.d. were positive in only 1/25 at week 0, but converted to positive in 6/19 of the DTH-negative patients who were retested at week-4. The objective response rate in patients who had measurable metastatic disease at the time of treatment was 0/15. With a median follow-up of > 5 years from date of DTH #1, median survival is 3 years, 5-year survival rate is 40%, and 11 patients are alive 3 to 12 years later. The 7 DTH+ patients survived a median of 2.5 years and 3 are still alive after 3, 4, and 7 years. One female patient who had lung, liver, and adrenal metastases had stable disease as her best response, subsequently had disease progression but remains alive more than 5 years later. The other 7 patients who survived more than 5 years had no measurable disease at the time treatment was initiated. This approach is feasible and the therapy is well tolerated; it would probably be best to limit further testing to patients with minimal tumor burdens, such as the adjuvant setting after primary treatment, or in patients with metastatic disease who can be rendered free of disease by surgery or systemic therapy.
Identification of Chondroitin Sulfate Proteoglycan-4 In Acute Myeloid Leukemia Using Monoclonal Antibody 225.28
Authors: Moon Fenton, Maura Gasparetto, Chang-Sook Hong, XinHui Wang, Clay Smith, Theresa Whiteside, Soldano Ferrone, Michael Boyiadzis
Journal: Blood (2011)